Geoff Meacham
Stock Analyst at B of A Securities
(3.38)
# 977
Out of 4,711 analysts
219
Total ratings
48.15%
Success rate
2.94%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Maintains: Buy | $42 → $45 | $26.49 | +69.88% | 5 | Nov 25, 2024 | |
| GILD Gilead Sciences | Initiates: Buy | $125 | $92.57 | +35.03% | 6 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Initiates: Neutral | $895 | $701.85 | +27.52% | 18 | Nov 14, 2024 | |
| BIIB Biogen | Initiates: Neutral | $190 | $146.47 | +29.72% | 12 | Nov 14, 2024 | |
| VRTX Vertex Pharmaceuticals | Initiates: Buy | $575 | $397.27 | +44.74% | 4 | Nov 14, 2024 | |
| AMGN Amgen | Initiates: Neutral | $335 | $263.38 | +27.19% | 10 | Nov 14, 2024 | |
| ABBV AbbVie | Maintains: Buy | $226 → $215 | $175.58 | +22.45% | 14 | Nov 12, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $1,150 → $1,100 | $767.76 | +43.27% | 9 | Oct 31, 2024 | |
| LYEL Lyell Immunopharma | Downgrades: Underperform | $6 → $1 | $0.61 | +63.21% | 3 | Oct 30, 2024 | |
| TYRA Tyra Biosciences | Upgrades: Buy | $22 → $31 | $14.00 | +121.43% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $115 | $65.66 | +75.14% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $110 | $39.39 | +179.26% | 9 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $10 | $0.49 | +1,936.25% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $145 | $98.05 | +47.88% | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $45 | $31.82 | +41.42% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $47.71 | +67.68% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $144.47 | +17.67% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $38 | $24.92 | +52.49% | 2 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $0.34 | +1,952.79% | 4 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $48 | $56.83 | -15.54% | 2 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $30 | $40.66 | -26.22% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $68 → $60 | $57.33 | +4.66% | 8 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 | $6.90 | +15.94% | 2 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $10.85 | +65.90% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $7.34 | +90.74% | 2 | Sep 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $2.87 | +178.75% | 4 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.40 | +1,114.29% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $14 | $1.85 | +656.76% | 3 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $45 | $26.36 | +70.71% | 6 | Apr 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $4.05 | +1,134.57% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.84 | +1,204.35% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $10.31 | -61.20% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $34 | $20.59 | +65.13% | 2 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.54 | +1,002.36% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $1.10 | +2,990.91% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $56 | $8.28 | +576.33% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $2.19 | +1,498.17% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $4.70 | +11,070.21% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.50 | +2,700.00% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $40.72 | +170.14% | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $6.15 | +225.20% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $2.47 | +709.72% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $9.45 | +111.64% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $2.75 | +227.27% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $7.62 | +687.40% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $7 | $3.80 | +84.21% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $14.14 | +62.66% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $68.84 | +19.12% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $359.58 | -73.58% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $3.19 | +2,407.84% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $40 | $46.24 | -13.49% | 7 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $135.42 | -0.31% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $15.22 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $4.45 | +349.44% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $36.26 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $245.44 | -35.63% | 5 | Nov 8, 2017 |
BridgeBio Pharma
Nov 25, 2024
Maintains: Buy
Price Target: $42 → $45
Current: $26.49
Upside: +69.88%
Gilead Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $125
Current: $92.57
Upside: +35.03%
Regeneron Pharmaceuticals
Nov 14, 2024
Initiates: Neutral
Price Target: $895
Current: $701.85
Upside: +27.52%
Biogen
Nov 14, 2024
Initiates: Neutral
Price Target: $190
Current: $146.47
Upside: +29.72%
Vertex Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $575
Current: $397.27
Upside: +44.74%
Amgen
Nov 14, 2024
Initiates: Neutral
Price Target: $335
Current: $263.38
Upside: +27.19%
AbbVie
Nov 12, 2024
Maintains: Buy
Price Target: $226 → $215
Current: $175.58
Upside: +22.45%
Eli Lilly
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $767.76
Upside: +43.27%
Lyell Immunopharma
Oct 30, 2024
Downgrades: Underperform
Price Target: $6 → $1
Current: $0.61
Upside: +63.21%
Tyra Biosciences
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $14.00
Upside: +121.43%
Sep 17, 2024
Maintains: Buy
Price Target: $130 → $115
Current: $65.66
Upside: +75.14%
Sep 13, 2024
Maintains: Neutral
Price Target: $130 → $110
Current: $39.39
Upside: +179.26%
Aug 19, 2024
Maintains: Buy
Price Target: $12 → $10
Current: $0.49
Upside: +1,936.25%
Jul 31, 2024
Maintains: Buy
Price Target: $150 → $145
Current: $98.05
Upside: +47.88%
Jun 13, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $31.82
Upside: +41.42%
May 10, 2024
Initiates: Buy
Price Target: $80
Current: $47.71
Upside: +67.68%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $144.47
Upside: +17.67%
Apr 12, 2024
Maintains: Buy
Price Target: $40 → $38
Current: $24.92
Upside: +52.49%
Mar 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.34
Upside: +1,952.79%
Mar 13, 2024
Maintains: Buy
Price Target: $24 → $48
Current: $56.83
Upside: -15.54%
Jan 3, 2024
Downgrades: Neutral
Price Target: $45 → $30
Current: $40.66
Upside: -26.22%
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $57.33
Upside: +4.66%
Dec 15, 2023
Downgrades: Neutral
Price Target: $8
Current: $6.90
Upside: +15.94%
Oct 10, 2023
Initiates: Buy
Price Target: $18
Current: $10.85
Upside: +65.90%
Sep 8, 2023
Downgrades: Neutral
Price Target: $23 → $14
Current: $7.34
Upside: +90.74%
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $2.87
Upside: +178.75%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.40
Upside: +1,114.29%
Jul 20, 2023
Reinstates: Buy
Price Target: $14
Current: $1.85
Upside: +656.76%
Apr 21, 2023
Maintains: Neutral
Price Target: $50 → $45
Current: $26.36
Upside: +70.71%
Jan 5, 2023
Initiates: Buy
Price Target: $50
Current: $4.05
Upside: +1,134.57%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.84
Upside: +1,204.35%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $10.31
Upside: -61.20%
Dec 29, 2021
Maintains: Buy
Price Target: $37 → $34
Current: $20.59
Upside: +65.13%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $2.54
Upside: +1,002.36%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $1.10
Upside: +2,990.91%
May 7, 2021
Upgrades: Buy
Price Target: $56
Current: $8.28
Upside: +576.33%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $2.19
Upside: +1,498.17%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $4.70
Upside: +11,070.21%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.50
Upside: +2,700.00%
Oct 5, 2020
Initiates: Buy
Price Target: $110
Current: $40.72
Upside: +170.14%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $6.15
Upside: +225.20%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $2.47
Upside: +709.72%
Aug 4, 2020
Initiates: Buy
Price Target: $20
Current: $9.45
Upside: +111.64%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $2.75
Upside: +227.27%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $7.62
Upside: +687.40%
Jun 25, 2020
Initiates: Underperform
Price Target: $7
Current: $3.80
Upside: +84.21%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $14.14
Upside: +62.66%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $68.84
Upside: +19.12%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $359.58
Upside: -73.58%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $3.19
Upside: +2,407.84%
Nov 6, 2018
Maintains: Equal-Weight
Price Target: $43 → $40
Current: $46.24
Upside: -13.49%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $135.42
Upside: -0.31%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $15.22
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $4.45
Upside: +349.44%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $36.26
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $245.44
Upside: -35.63%